[{"orgOrder":0,"company":"MARATHON PHARMS","sponsor":"Aquestive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Diazepam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"MARATHON PHARMS","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.089999999999999997,"dosageForm":"Film, Soluble","sponsorNew":"MARATHON PHARMS \/ MARATHON PHARMS","highestDevelopmentStatusID":"15","companyTruncated":"MARATHON PHARMS \/ MARATHON PHARMS"}]

Find Clinical Drug Pipeline Developments & Deals by MARATHON PHARMS

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : The proceeds will help to execute on advancing company's key clinical and commercial initiatives, including the resubmission of its NDA for FDA approval of lead product Libervant™ Buccal Film and ongoing clinical trial for AQST-108.

                          Product Name : Libervant

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          November 23, 2020

                          Lead Product(s) : Diazepam

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Recipient : Aquestive Therapeutics

                          Deal Size : $85.0 million

                          Deal Type : Agreement

                          blank

                          02

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : MP-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 23, 2014

                          Lead Product(s) : MP-101

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : MP-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 17, 2014

                          Lead Product(s) : MP-101

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank